Vaccex Inc. (fka VCEX)

[rstar]

The Vaccex Corporate Strategy
The Vaccex corporate strategy is to advance controlled and sustained release formulations of potent anti-cancer drug for intra-tumoral administration and leverage the uniqueness of this treatment regimen to design and develop an array of cancer treatments either as stand-alone treatments or in combination with other therapies. The Company and its collaborators are currently planning clinical studies of controlled and sustained release intra-tumoral immunotherapies in metastasized colorectal and breast cancer.
Moving forward, the Company expects that it will continue to invest in its core clinical program areas and will also remain opportunistic in evaluating Investigator Sponsored Trials (“ISTs”) as well as partnering and licensing opportunities. The controlled and sustained release formulation platform is protected by patents, covering both product and process, some of which the Company believes can be maintained into 2038.